Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.8
2.5
Journals
Epigenomes
Special Issues
Epigenetics of Pancreatic Cancer
share announcement

Epigenetics of Pancreatic Cancer

A special issue of Epigenomes (ISSN 2075-4655).

Deadline for manuscript submissions: closed (15 May 2018) | Viewed by 34904

Special Issue Editors

Dr. Martin E. Fernandez-Zapico

E-Mail Website
Guest Editor
Schulze Center for Novel Therapeutics, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Interests: pancreatic cancer; tumor microenvironment; histone methylation; nuclear and chromatin organization
Special Issues, Collections and Topics in MDPI journals
Dr. Christopher Pin

E-Mail Website
Guest Editor
Division Head and Scientist, Genetics and Development, Children's Health Research InstituteAssociate Professor, Depts. of Paediatrics, Physiology and Pharmacology, and OncologySchulich School of Medicine and Dentistry, University of Western Ontario
Interests: epigenetic regulation of pancreatic development and disease; acinar-to-duct cell metaplasia; unfolded protein response; ER stress; acinar cell physiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the role of epigenetics in pancreatic cancer, a dismal disease predicted to be second cause of cancer death by 2030. This aggressive and rapidly-disseminated epithelial neoplasm is highly resistant to conventional chemotherapeutic and radiation-based treatments. The past several decades of pancreatic cancer research have yielded a tremendous amount of knowledge about the genetics of tumor cells; however, this knowledge has not translated into significant clinical advances in treatment and prevention. These genetic-based drivers of pancreatic cancer have been well studied, but they do not account for all of the phenotypic and molecular alterations demonstrated by tumor cells. Pancreatic cancer initiation and progression is the result of a heterogeneous and dynamic combination of both genetic and epigenetic mechanisms. With the identification of epigenetic alterations seen in early pancreatic preneoplastic lesions through the development of pancreatic cancer, there implies an inherent complexity in epigenetic changes that occurs in parallel to genetic changes. This Special Issue will discuss on the present knowledge in field pancreatic cancer epigenetics and will be composed of the following works (see planned papers)

Dr. Martin E. Fernandez-Zapico
Dr. Christopher Pin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • epigenetics
  • chromatin dynamics
  • therapeutic
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (8 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

4 pages, 170 KiB  
Editorial
New Aspects of the Epigenetics of Pancreatic Carcinogenesis
by Murat Toruner, Martin E. Fernandez-Zapico and Christopher L. Pin
Epigenomes 2020, 4(3), 18; https://doi.org/10.3390/epigenomes4030018 - 31 Aug 2020
Cited by 3 | Viewed by 3175
Abstract
Pancreatic cancer remains among the deadliest forms of cancer with a 5 year survival rate less than 10%. With increasing numbers being observed, there is an urgent need to elucidate the pathogenesis of pancreatic cancer. While both contribute to disease progression, neither genetic [...] Read more.
Pancreatic cancer remains among the deadliest forms of cancer with a 5 year survival rate less than 10%. With increasing numbers being observed, there is an urgent need to elucidate the pathogenesis of pancreatic cancer. While both contribute to disease progression, neither genetic nor environmental factors completely explain susceptibility or pathogenesis. Defining the links between genetic and environmental events represents an opportunity to understand the pathogenesis of pancreatic cancer. Epigenetics, the study of mitotically heritable changes in genome function without a change in nucleotide sequence, is an emerging field of research in pancreatic cancer. The main epigenetic mechanisms include DNA methylation, histone modifications and RNA interference, all of which are altered by changes to the environment. Epigenetic mechanisms are being investigated to clarify the underlying pathogenesis of pancreatic cancer including an increasing number of studies examining the role as possible diagnostic and prognostic biomarkers. These mechanisms also provide targets for promising new therapeutic approaches for this devastating malignancy. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer 2.0)

Review

Jump to: Editorial

18 pages, 325 KiB  
Review
Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma
by Joyce K. Thompson and Filip Bednar
Epigenomes 2021, 5(4), 20; https://doi.org/10.3390/epigenomes5040020 - 27 Sep 2021
Cited by 4 | Viewed by 3393
Abstract
Pancreatic cancer is a molecularly heterogeneous disease. Epigenetic changes and epigenetic regulatory mechanisms underlie at least some of this heterogeneity and contribute to the evolution of aggressive tumor biology in patients and the tumor’s intrinsic resistance to therapy. Here we review our current [...] Read more.
Pancreatic cancer is a molecularly heterogeneous disease. Epigenetic changes and epigenetic regulatory mechanisms underlie at least some of this heterogeneity and contribute to the evolution of aggressive tumor biology in patients and the tumor’s intrinsic resistance to therapy. Here we review our current understanding of epigenetic dysregulation in pancreatic cancer and how it is contributing to our efforts in early diagnosis, predictive and prognostic biomarker development and new therapeutic approaches in this deadly cancer. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer 2.0)
11 pages, 251 KiB  
Review
Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update
by Stine Dam Henriksen and Ole Thorlacius-Ussing
Epigenomes 2021, 5(2), 8; https://doi.org/10.3390/epigenomes5020008 - 9 Apr 2021
Cited by 12 | Viewed by 4709
Abstract
Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim [...] Read more.
Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim of this paper is to do an update on cell-free DNA methylation as blood-based biomarkers for pancreatic adenocarcinoma. The current literature including our studies clearly indicates that cell-free DNA methylation has the potential as blood-based diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. However, still no clinical applicable biomarker for pancreatic adenocarcinoma based on DNA methylation do exist. Further well-designed validation studies are needed. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer 2.0)
19 pages, 328 KiB  
Review
Epigenomics of Pancreatic Cancer: A Critical Role for Epigenome-Wide Studies
by Rahul R. Singh, Katie M. Reindl and Rick J. Jansen
Epigenomes 2019, 3(1), 5; https://doi.org/10.3390/epigenomes3010005 - 19 Jan 2019
Cited by 4 | Viewed by 5537
Abstract
Several challenges present themselves when discussing current approaches to the prevention or treatment of pancreatic cancer. Up to 45% of the risk of pancreatic cancer is attributed to unknown causes, making effective prevention programs difficult to design. The most common type of pancreatic [...] Read more.
Several challenges present themselves when discussing current approaches to the prevention or treatment of pancreatic cancer. Up to 45% of the risk of pancreatic cancer is attributed to unknown causes, making effective prevention programs difficult to design. The most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), is generally diagnosed at a late stage, leading to a poor prognosis and 5-year survival estimate. PDAC tumors are heterogeneous, leading to many identified cell subtypes within one patient’s primary tumor. This explains why there is a high frequency of tumors that are resistant to standard treatments, leading to high relapse rates. This review will discuss how epigenetic technologies and epigenome-wide association studies have been used to address some of these challenges and the future promises these approaches hold. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer)
19 pages, 745 KiB  
Review
Nuclear Envelope Regulation of Oncogenic Processes: Roles in Pancreatic Cancer
by Claudia C. Preston and Randolph S. Faustino
Epigenomes 2018, 2(3), 15; https://doi.org/10.3390/epigenomes2030015 - 2 Sep 2018
Cited by 2 | Viewed by 7664
Abstract
Pancreatic cancer is an aggressive and intractable malignancy with high mortality. This is due in part to a high resistance to chemotherapeutics and radiation treatment conferred by diverse regulatory mechanisms. Among these, constituents of the nuclear envelope play a significant role in regulating [...] Read more.
Pancreatic cancer is an aggressive and intractable malignancy with high mortality. This is due in part to a high resistance to chemotherapeutics and radiation treatment conferred by diverse regulatory mechanisms. Among these, constituents of the nuclear envelope play a significant role in regulating oncogenesis and pancreatic tumor biology, and this review focuses on three specific components and their roles in cancer. The LINC complex is a nuclear envelope component formed by proteins with SUN and KASH domains that interact in the periplasmic space of the nuclear envelope. These interactions functionally and structurally couple the cytoskeleton to chromatin and facilitates gene regulation informed by cytoplasmic activity. Furthermore, cancer cell invasiveness is impacted by LINC complex biology. The nuclear lamina is adjacent to the inner nuclear membrane of the nuclear envelope and can actively regulate chromatin in addition to providing structural integrity to the nucleus. A disrupted lamina can impart biophysical compromise to nuclear structure and function, as well as form dysfunctional micronuclei that may lead to genomic instability and chromothripsis. In close relationship to the nuclear lamina is the nuclear pore complex, a large megadalton structure that spans both outer and inner membranes of the nuclear envelope. The nuclear pore complex mediates bidirectional nucleocytoplasmic transport and is comprised of specialized proteins called nucleoporins that are overexpressed in many cancers and are diagnostic markers for oncogenesis. Furthermore, recent demonstration of gene regulatory functions for discrete nucleoporins independent of their nuclear trafficking function suggests that these proteins may contribute more to malignant phenotypes beyond serving as biomarkers. The nuclear envelope is thus a complex, intricate regulator of cell signaling, with roles in pancreatic tumorigenesis and general oncogenic transformation. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer)
►▼ Show Figures

Figure 1

13 pages, 704 KiB  
Review
Recent Advances in Chromatin Mechanisms Controlling Pancreatic Carcinogenesis
by Thomas Hank and Andrew S. Liss
Epigenomes 2018, 2(2), 11; https://doi.org/10.3390/epigenomes2020011 - 20 Jun 2018
Cited by 2 | Viewed by 5314
Abstract
Pancreatic ductal adenocarcinoma has a heterogeneous genetic landscape, marked by frequent mutation of KRAS, CDKN2A, TP53, and SMAD4, resulting in poor responses to conventional therapeutic regimens. Over the past decade, increased understanding of the genetic underpinnings of this lethal [...] Read more.
Pancreatic ductal adenocarcinoma has a heterogeneous genetic landscape, marked by frequent mutation of KRAS, CDKN2A, TP53, and SMAD4, resulting in poor responses to conventional therapeutic regimens. Over the past decade, increased understanding of the genetic underpinnings of this lethal cancer has yielded several different characterizations of pancreatic cancer subtypes. However, not all phenotypes and changes in pancreatic cancer can be explained by these findings. New insights on epigenetic modifications associated with pancreatic carcinogenesis have highlighted additional pathways, other than gene mutations, among which chromatin regulation plays a dominant role. Gene expression is highly regulated by subtle changes in chromatin configuration. The underlying mechanism is dominated by reversible post-translational histone modifications. In addition, there is growing evidence that different chromatin mechanisms interact with one another, contributing to the diversity of pancreatic carcinogenesis. This review highlights recent work characterizing chromatin regulatory mechanisms associated with pancreatic carcinogenesis as well as future directions of this emerging research. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer)
►▼ Show Figures

Graphical abstract

28 pages, 1250 KiB  
Review
The Epigenetic Landscape of Pancreatic Cancer Stem Cells
by Sladjana Zagorac, Laura Garcia-Bermejo and Bruno Sainz, Jr.
Epigenomes 2018, 2(2), 10; https://doi.org/10.3390/epigenomes2020010 - 14 Jun 2018
Cited by 9 | Viewed by 9865
Abstract
Data now indicates that in addition to genetic alterations/mutations, human cancer cells exhibit important changes in their epigenome. In the context of this review, we define the epigenome as the chemical compounds and/or proteins that can interact with nuclear DNA to direct the [...] Read more.
Data now indicates that in addition to genetic alterations/mutations, human cancer cells exhibit important changes in their epigenome. In the context of this review, we define the epigenome as the chemical compounds and/or proteins that can interact with nuclear DNA to direct the specific and localized activation or silencing of genes to control the production of cellular proteins (directly or indirectly) in a given cell. Our ever-growing knowledge of how the epigenome can affect cellular processes has largely changed our view of cancer being a solely genetic disease. Nowadays, cancer is largely defined and characterized by the dynamic changes in both the genome and epigenome, which function together and contribute concomitantly to cancer initiation and progression. Since epigenetic modifications are crucial processes involved in controlling cellular identity and lineage fate, perturbations in this layer of gene regulation can contribute to the acquisition of new cellular characteristics different than those that were “initially” intended. For example, aberrant epigenetic alterations may transform normal non-cancer cells into cancer stem cells (CSCs), endowing them with the loss of differentiation and the acquisition of stem-like characteristics. In this review, we will focus our discussion on CSCs in the context of pancreatic ductal adenocarcinoma (PDAC). We will discuss how different epigenetic modifications create a landscape that can impact CSC identity and the way this small sub-population of cells contributes to tumor initiation, progression, and resistance to therapy. Moreover, we will highlight the latest discoveries in epigenetic-based therapies as a means of targeting CSCs. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer)
►▼ Show Figures

Figure 1

17 pages, 1285 KiB  
Review
Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic Cancer
by Feda H. Hamdan and Steven A. Johnsen
Epigenomes 2018, 2(2), 8; https://doi.org/10.3390/epigenomes2020008 - 31 May 2018
Cited by 3 | Viewed by 5648
Abstract
While the mortality rates of cancer are generally declining, pancreatic cancer persists to be an exception with a 5-year-survival rate of less than 7%. Late diagnosis and resistance to conventional therapies contribute to high mortality rates in spite of the remarkable recent advances [...] Read more.
While the mortality rates of cancer are generally declining, pancreatic cancer persists to be an exception with a 5-year-survival rate of less than 7%. Late diagnosis and resistance to conventional therapies contribute to high mortality rates in spite of the remarkable recent advances in cancer management and research. Consequently, there is an urgent need to find new and unconventional therapeutic targets to improve prognosis and survival of pancreatic cancer patients. In this review, we discuss the transcriptional effects of the most widely used epigenetic inhibitors in pancreatic cancer focusing on Bromodomain and Extraterminal domain (BET) and Histone Deacetylase (HDAC) inhibitors, which are currently highly promising therapeutic options. We suggest that these inhibitors can be better utilized at lower doses which exploit their transcriptional modulatory effects on pancreatic cancer transcriptional programs directed by specific factors such as MYC and Forkhead Box A1 (FOXA1), rather than simply based on their anti-proliferative effects. This approach can potentially help avoid the intolerable adverse events frequently elicited by the use of these treatments at higher doses. In particular, we underscore the crucial role of distal regulatory elements in mediating the specific effects of these epigenetic inhibitors and propose using them in a more selective and prudent manner. Full article
(This article belongs to the Special Issue Epigenetics of Pancreatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-8
Back to TopTop